XTL Biopharmaceuticals announced it will acquire Psyga Bio, a biotech company specializing in psychedelic and functional mushroom-derived products, including psilocybin therapies. Psyga Bio operates a licensed GMP pharmaceutical facility and has seven approved Phase 2a clinical trials targeting mental health and neurological disorders. The acquisition, structured through a share exchange without upfront cash, positions XTL as a leading player in the expanding psychedelic therapeutics market amid recent U.S. regulatory support for psychedelic drug research. Psyga will become a wholly owned subsidiary, and the deal includes milestone-based incentives tied to clinical and commercial progress. This move aims to leverage Psyga’s clinical pipeline and manufacturing capabilities to accelerate development and commercialization in this emerging sector.
Purecore Metals Inc. has signed a non-binding letter of intent with Skyharbour Resources to acquire an option to earn up to 100% interest in the Yurchison uranium property in Saskatchewan's Athabasca Basin. The property covers over 35,000 hectares an...
Shirofune has introduced Walmart Connect, an integration that allows advertisers and agencies to manage Walmart retail media campaigns alongside other digital channels within a single platform. This automation reduces manual bid adjustments and repor...
Point completed a $508.6 million rated asset-backed securitization of its Home Equity Investment (HEI) assets, marking the largest transaction ever in the HEI asset class. The deal attracted over 30 institutional investors and priced at significantly...
The global reactive hot melt adhesives market is projected to grow from $2.02 billion in 2025 to $4.29 billion by 2035, at a CAGR of 7.72%. Growth is driven by regulations limiting solvent-based adhesives, increased use of polyurethane adhesives in a...
Red Light Holland, after acquiring Filament Health, has expanded its capabilities in pharmaceutical-grade psilocybin development. Filament completed a shipment of its botanical psilocybin drug candidate, PEX010, to the European Union to support multi...
